This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/company/
n6http://linked.opendata.cz/resource/mesh/concept/
n19http://linked.opendata.cz/resource/drugbank/drug/DB01028/identifier/chemspider/
n18http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB01028/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01028/identifier/pharmgkb/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01028/identifier/kegg-compound/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n17http://linked.opendata.cz/resource/drugbank/drug/DB01028/identifier/pubchem-compound/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01028/identifier/pubchem-substance/
xsdhhttp://www.w3.org/2001/XMLSchema#
n21http://linked.opendata.cz/resource/drugbank/drug/DB01028/identifier/kegg-drug/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01028/identifier/drugbank/
n8http://linked.opendata.cz/resource/atc/
n7http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01028
rdf:type
n3:Drug
n3:description
An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180)
n3:group
approved
n3:indication
For use in the induction and maintenance of general anesthesia
owl:sameAs
n10:DB01028 n18:DB01028
dcterms:title
Methoxyflurane
adms:identifier
n12:Methoxyflurane n15:46508879 n16:PA450434 n17:4116 n19:3973 n20:C07517 n21:D00544 n22:DB01028
n3:mechanismOfAction
Methoxyflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Methoxyflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Methoxyflurane also binds to the GABA receptor, the large conductance Ca<sup>2+</sup> activated potassium channel, the glutamate receptor and the glycine receptor.
n3:packager
n14:271B55E9-363D-11E5-9242-09173F13E4C5
n3:synonym
Penthrane Methoflurane Methoxyfluranum Methoxyfluran Metoxiflurano Methoxyfluoran Methyl 1,1-difluoro-2,2-dichloroethyl ether
n3:toxicity
LD<sub>50</sub>=3600 mg/kg (Orally in rats). Symptoms of overexposure include eye irritation, CNS depression, analgesia, anesthesia, seizures, respiratory depression, and liver and kidney damage.
n5:hasConcept
n6:M0013605
n3:IUPAC-Name
n4:271B55EE-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B55F4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B55F3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B55F0-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B55F1-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B55F2-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B55EC-363D-11E5-9242-09173F13E4C5 n4:271B5603-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5606-363D-11E5-9242-09173F13E4C5 n4:271B55EA-363D-11E5-9242-09173F13E4C5 n4:271B55ED-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B55EB-363D-11E5-9242-09173F13E4C5
n7:hasATCCode
n8:N02BG09
n3:H-Bond-Acceptor-Count
n4:271B55FA-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B55FB-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B55F5-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B55F6-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B55F8-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B55F7-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B55F9-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
76-38-0
n3:category
n3:Bioavailability
n4:271B55FF-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B5605-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5601-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5602-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5604-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B55FE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B55FD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5600-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B55EF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B55FC-363D-11E5-9242-09173F13E4C5